{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:51:18Z","timestamp":1785873078717,"version":"3.56.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472188"],"award-info":[{"award-number":["82472188"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272204"],"award-info":[{"award-number":["82272204"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006180","name":"Technology Development","doi-asserted-by":"publisher","award":["2024ZY01012"],"award-info":[{"award-number":["2024ZY01012"]}],"id":[{"id":"10.13039\/100006180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018553","name":"Science and Technology Plan Project of Wenzhou Municipality","doi-asserted-by":"publisher","award":["ZY2023005"],"award-info":[{"award-number":["ZY2023005"]}],"id":[{"id":"10.13039\/501100018553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018553","name":"Science and Technology Plan Project of Wenzhou Municipality","doi-asserted-by":"publisher","award":["ZY2021010"],"award-info":[{"award-number":["ZY2021010"]}],"id":[{"id":"10.13039\/501100018553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bcp.2026.118136","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:43:04Z","timestamp":1780555384000},"page":"118136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P1","title":["Valsartan alleviates acetaminophen-induced hepatotoxicity by activating fibroblast growth factor 21 in acute liver injury in mice"],"prefix":"10.1016","volume":"251","author":[{"given":"Junwei","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingyan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suntao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjia","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaicheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darong","family":"Hai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingye","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuebo","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.118136_b0005","doi-asserted-by":"crossref","DOI":"10.1080\/17425255.2023.2223959","article-title":"Paracetamol (acetaminophen) overdose and hepatotoxicity: mechanism, treatment, prevention measures, and estimates of burden of disease","author":"Chidiac","year":"2023","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118136_b0010","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.jhep.2017.07.005","article-title":"Acetaminophen (APAP) hepatotoxicity-Isn't it time for APAP to go away?","volume":"67","author":"Lee","year":"2017","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118136_b0015","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.cld.2018.01.007","article-title":"Acetaminophen (APAP or N-Acetyl-p-Aminophenol) and Acute Liver failure","volume":"22","author":"Bunchorntavakul","year":"2018","journal-title":"Clin. Liver Dis."},{"issue":"8","key":"10.1016\/j.bcp.2026.118136_b0020","first-page":"1202","article-title":"The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative stress","volume":"19","author":"Raghu","year":"2021","journal-title":"Curr. Neuropharmacol."},{"issue":"11","key":"10.1016\/j.bcp.2026.118136_b0025","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1080\/17425255.2022.2151893","article-title":"Acetaminophen toxicity and overdose: current understanding and future directions for NAC dosing regimens","volume":"18","author":"Jankovi\u0107","year":"2022","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118136_b0030","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/15563650.2021.1984503","article-title":"Evaluation of N-acetylcysteine dose for the treatment of massive acetaminophen ingestion","volume":"60","author":"Lewis","year":"2022","journal-title":"Clin. Toxicol. (Phila.)"},{"issue":"3","key":"10.1016\/j.bcp.2026.118136_b0035","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/hep.27060","article-title":"Fibroblast growth factor 21 protects against acetaminophen-induced hepatotoxicity by potentiating peroxisome proliferator-activated receptor coactivator protein-1\u03b1-mediated antioxidant capacity in mice","volume":"60","author":"Ye","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2026.118136_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2024.111379","article-title":"Fibroblast growth factor 21 alleviates acetaminophen induced acute liver injury by activating Sirt1 mediated autophagy","volume":"123","author":"Xu","year":"2024","journal-title":"Cell. Signal."},{"issue":"3","key":"10.1016\/j.bcp.2026.118136_b0045","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/jcmm.17144","article-title":"FGF21 alleviates acute liver injury by inducing the SIRT1-autophagy signalling pathway","volume":"26","author":"Yang","year":"2022","journal-title":"J. Cell Mol. Med."},{"issue":"5","key":"10.1016\/j.bcp.2026.118136_b0050","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.21037\/apm-22-503","article-title":"Efficacy and safety of sacubitril\/valsartan in the treatment of middle-aged and elderly patients with hypertension: a systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Wu","year":"2022","journal-title":"Ann Palliat Med."},{"issue":"9426","key":"10.1016\/j.bcp.2026.118136_b0055","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.bcp.2026.118136_b0060","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"Valsartan Heart failure Trial investigators. a randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118136_b0065","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13098-024-01284-1","article-title":"Sacubitril\/valsartan ameliorates tubulointerstitial fibrosis by restoring mitochondrial homeostasis in diabetic kidney disease","volume":"16","author":"Zhang","year":"2024","journal-title":"Diabetol. Metab. Syndr."},{"issue":"961","key":"10.1016\/j.bcp.2026.118136_b0070","article-title":"Sacubitril\/valsartan attenuates myocardial inflammation, hypertrophy, and fibrosis in rats with heart failure with preserved ejection fraction","volume":"15","author":"Shi","year":"2023","journal-title":"Eur. J. Pharmacol."},{"issue":"Pt 1","key":"10.1016\/j.bcp.2026.118136_b0075","article-title":"Cardiometabolic effects of sacubitril\/valsartan in a rat model of heart failure with preserved ejection fraction","volume":"230","author":"Mora\u00f1a-Fern\u00e1ndez","year":"2024","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118136_b0080","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12012-020-09590-6","article-title":"The protective Effects of compound 21 and Valsartan in Isoproterenol-Induced Myocardial Injury in Rats","volume":"21","author":"Ulutas","year":"2021","journal-title":"Cardiovasc. Toxicol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118136_b0085","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1177\/1470320313507123","article-title":"Protective effects of aliskiren and valsartan in mice with diabetic nephropathy","volume":"15","author":"Wang","year":"2014","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"issue":"1","key":"10.1016\/j.bcp.2026.118136_b0090","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12933-025-02627-6","article-title":"Sacubitril\/Valsartan partially alleviates myocardial infarction injury by activating the FGF21 signaling pathway via PPARs","volume":"24","author":"Wei","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118136_b0095","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.cmet.2013.04.005","article-title":"Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice","volume":"17","author":"Lin","year":"2013","journal-title":"Cell Metab."},{"issue":"5","key":"10.1016\/j.bcp.2026.118136_b0100","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/01.mnh.0000174397.59100.89","article-title":"Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers","volume":"14","author":"Sierra","year":"2005","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"issue":"2","key":"10.1016\/j.bcp.2026.118136_b0105","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41569-019-0244-8","article-title":"Counter-regulatory renin-angiotensin system in cardiovascular disease","volume":"17","author":"Paz Ocaranza","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118136_b0110","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1152\/physrev.00023.2016","article-title":"The ACE2\/Angiotensin-(1-7)\/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7)","volume":"98","author":"Santos","year":"2018","journal-title":"Physiol. Rev."},{"issue":"8","key":"10.1016\/j.bcp.2026.118136_b0115","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCRESAHA.113.301077","article-title":"Discovery and characterization of alamandine: a novel component of the renin-angiotensin system","volume":"112","author":"Lautner","year":"2013","journal-title":"Circ. Res."},{"key":"10.1016\/j.bcp.2026.118136_b0120","doi-asserted-by":"crossref","unstructured":"Huang Z, Wang H, Chun C, Li X, Xu S, Zhao Y. Self-assembled FGF21 nanoparticles alleviate drug-induced acute liver injury.Front Pharmacol. 2023;13:1084799. Published 2023 Jan 10.","DOI":"10.3389\/fphar.2022.1084799"},{"key":"10.1016\/j.bcp.2026.118136_b0125","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.redox.2018.04.019","article-title":"Mechanisms of acetaminophen-induced liver injury and its implications for therapeutic interventions","volume":"17","author":"Yan","year":"2018","journal-title":"Redox Biol."},{"key":"10.1016\/j.bcp.2026.118136_b0130","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1146\/annurev-nutr-071816-064800","article-title":"Fibroblast Growth factor 21: a Versatile Regulator of Metabolic Homeostasis","volume":"38","author":"BonDurant","year":"2018","journal-title":"Annu. Rev. Nutr."},{"issue":"6","key":"10.1016\/j.bcp.2026.118136_b0135","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","article-title":"FGF-21 as a novel metabolic regulator","volume":"115","author":"Kharitonenkov","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2026.118136_b0140","doi-asserted-by":"crossref","unstructured":"Yang M, Liu C, Jiang N, et al. Fibroblast growth factor 21 in metabolic syndrome. Front Endocrinol (Lausanne). 2023;14:1220426. Published 2023 Jul 27.","DOI":"10.3389\/fendo.2023.1220426"},{"issue":"2","key":"10.1016\/j.bcp.2026.118136_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2024.100018","article-title":"Pharmacological treatment for metabolic dysfunction-associated steatotic liver disease and related disorders: current and emerging therapeutic options","volume":"77","author":"Zhang","year":"2025","journal-title":"Pharmacol. Rev."},{"issue":"6","key":"10.1016\/j.bcp.2026.118136_b0150","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.cmet.2007.05.002","article-title":"Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states","volume":"5","author":"Badman","year":"2007","journal-title":"Cell Metab."},{"issue":"6","key":"10.1016\/j.bcp.2026.118136_b0155","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cmet.2007.05.003","article-title":"Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21","volume":"5","author":"Inagaki","year":"2007","journal-title":"Cell Metab."},{"key":"10.1016\/j.bcp.2026.118136_b0160","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1089214","article-title":"The potential function and clinical application of FGF21 in metabolic diseases","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118136_b0165","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s42255-021-00354-2","article-title":"Metabolic Messengers: FGF21","volume":"3","author":"Flippo","year":"2021","journal-title":"Nat Metab."},{"issue":"5","key":"10.1016\/j.bcp.2026.118136_b0170","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1042\/BJ20151085","article-title":"Circulating FGF21 proteolytic processing mediated by fibroblast activation protein","volume":"473","author":"Zhen","year":"2016","journal-title":"Biochem. J"},{"key":"10.1016\/j.bcp.2026.118136_b0175","doi-asserted-by":"crossref","first-page":"5986","DOI":"10.1074\/jbc.M115.710582","article-title":"Fibroblast activation protein cleaves and inactivates fibroblast growth factor 21","volume":"291","author":"Dunshee","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2026.118136_b0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151269","article-title":"Human FGF-21 is a Substrate of Fibroblast Activation Protein","volume":"11","author":"Coppage","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2026.118136_b0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058575","article-title":"Rational design of a fibroblast growth factor 21-based clinical candidate, L Y2405319","volume":"8","author":"Kharitonenkov","year":"2013","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.bcp.2026.118136_b0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049345","article-title":"Rationale-based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes","volume":"7","author":"Hecht","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.bcp.2026.118136_b0195","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/01.HYP.0000123072.34629.57","article-title":"Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity","volume":"43","author":"Benson","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2026.118136_b0200","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1475-2840-4-6","article-title":"Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome","volume":"4","author":"Vitale","year":"2005","journal-title":"Cardiovasc. Diabetol."},{"issue":"5 Suppl 1","key":"10.1016\/j.bcp.2026.118136_b0205","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.amjmed.2006.01.011","article-title":"New treatment strategies for patients with hypertension and insulin resistance","volume":"119","author":"Kurtz","year":"2006","journal-title":"Am. J. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.118136_b0210","doi-asserted-by":"crossref","first-page":"E287","DOI":"10.1152\/ajpendo.00440.2004","article-title":"PPARgamma-mediated insulin sensitization: the importance of fat versus muscle","volume":"288","author":"Kintscher","year":"2005","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.bcp.2026.118136_b0215","first-page":"64","article-title":"PPAR gamma: an essential role in metabolic control","volume":"11","author":"Fajas","year":"2001","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.bcp.2026.118136_b0220","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1074911","article-title":"PPAR\u03b1: an emerging target of metabolic syndrome, neurodegenerative and cardiovascular diseases","volume":"13","author":"Lin","year":"2022","journal-title":"Front Endocrinol (lausanne)."},{"issue":"2","key":"10.1016\/j.bcp.2026.118136_b0225","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.bbrc.2018.04.157","article-title":"FGF21 mediates the protective effect of fenofibrate against acetaminophen -induced hepatotoxicity via activating autophagy in mice","volume":"503","author":"Zhang","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"9","key":"10.1016\/j.bcp.2026.118136_b0230","first-page":"728","article-title":"Pharmacokinetics and safety of sacubitril\/valsartan (LCZ696) in patients with mild and moderate hepatic impairment","volume":"55","author":"Kulmatycki","year":"2017","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.118136_b0235","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/AC.67.1.2146570","article-title":"Cardioprotective effects of zofenopril, enalapril and valsartan against ischaemia\/reperfusion injury as well as doxorubicin cardiotoxicity","volume":"67","author":"Bozcali","year":"2012","journal-title":"Acta Cardiol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118136_b0240","doi-asserted-by":"crossref","first-page":"575","DOI":"10.5603\/CJ.a2018.0048","article-title":"Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats","volume":"26","author":"Miyoshi","year":"2019","journal-title":"Cardiol. J."},{"key":"10.1016\/j.bcp.2026.118136_b0245","article-title":"Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure.BMC","volume":"20(1):23","author":"Dizaye","year":"2019","journal-title":"Pharmacol. Toxicol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118136_b0250","doi-asserted-by":"crossref","first-page":"9070","DOI":"10.1080\/21655979.2021.1981799","article-title":"Valsartan alleviates the blood-brain barrier dysfunction in db\/db diabetic mice","volume":"12","author":"Cai","year":"2021","journal-title":"Bioengineered"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226004715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226004715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:41:39Z","timestamp":1785872499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226004715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":50,"alternative-id":["S0006295226004715"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118136","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Valsartan alleviates acetaminophen-induced hepatotoxicity by activating fibroblast growth factor 21 in acute liver injury in mice","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118136","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118136"}}